Conduct a rapid pricing and market access (P&MA) assessment across the US and EU5 in order to determ...
Read moreOur client had concerns as to whether the clinical end-points in their phase III trial were relevant...
Read moreOur clients have been developing new drugs for crowded, rapidly evolving therapy areas, with uncerta...
Read moreOur client was seeking to launch and in-licensed product in the EU, following launch in the US.
Read moreOur client wanted to organise an advisory board to seek guidance from a range of stakeholders within...
Read moreOur client needed to understand the clinical and economic evidence requirements that drive payer dec...
Read moreOur client wanted to gain an understanding of payer willingness to pay and determine the likely clin...
Read moreOur client wanted to gain a better understanding of current and forthcoming policy measures affectin...
Read moreDevelopment and submission of payer communication materials and pricing and reimbursement dossiers f...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more